BioLineRx Ltd. — Form F-1
Filed September 25, 2026 · analyzed by the Registration Agent
F-1
— Neutral
significance 28/100
What the filing says
BioLineRx Ltd., an Israeli clinical-stage biopharmaceutical company, filed Form F-1 on September 25, 2026 to register for resale 2,023,382 ADSs (representing 1.214 billion ordinary shares) issuable upon exercise of warrants issued August 31, 2026 to Armistice Capital Master Fund Ltd. The August 2026 offering generated ~$3.75M gross proceeds ($3.3M net) at $2.78–$2.7799 per ADS/warrant unit; company received $0 from this resale registration but may receive up to $5.6M if all warrants are exercised for cash. Armistice holds 2.114 billion ordinary shares pre-offering and would hold 21.4% post-full resale.
Why this rating
Secondary resale of warrants; minimal direct capital impact to company. Dilution and price pressure are real but are routine warrant exercises. Company size and burn rate unclear; estimated market cap ~$12M–$14M (ADS at $2.56 × 4.98M ADSs), making this a non-transformative financing event.
See more from September 25, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.